The term AI987662 Activators likely refers to a group of compounds that can specifically activate a biological or chemical entity denoted as AI987662. The identification and characterization of such activators would involve a series of methodical approaches. Typically, the process begins with high-throughput screening (HTS), wherein a large library of chemicals is tested for an ability to activate the AI987662 entity. This screening can be facilitated by using reporter assays, wherein a detectable signal, such as luminescence or fluorescence, is produced in response to the activation of AI987662. Compounds that result in a significant increase in the reporter signal are identified as potential activators. Subsequent to HTS, these compounds undergo further validation assays to confirm their activity. This may include dose-response experiments to determine the concentration at which the compound is most effective in activating AI987662.
Following the initial discovery phase, detailed investigations are performed to elucidate the mechanisms by which these activators interact with AI987662. This could involve a combination of biophysical techniques such as X-ray crystallography or cryo-electron microscopy, which can provide high-resolution structural details of the AI987662 in complex with the activator. Binding studies, possibly utilizing surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC), can offer quantitative data on the binding affinity and kinetics. Additionally, structure-activity relationship (SAR) studies are conducted to understand how different chemical modifications of the activators affect their ability to activate AI987662. Through SAR studies, the essential chemical features required for activation can be pinpointed, leading to the optimization of the activator compounds. Mutagenesis experiments might also be employed, especially if AI987662 is a protein, to identify the critical regions necessary for the interaction and activation by the compounds. These comprehensive analyses contribute to a clearer understanding of the relationship between the structure of the activators and their activation function, laying the groundwork for further characterization and classification of the compounds within the AI987662 Activators group.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylyl cyclase, consequently increasing levels of cyclic AMP (cAMP) in cells. Elevated cAMP can activate PKA which may phosphorylate and enhance the function of AI987662 if it is a substrate for PKA. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC) which can phosphorylate a range of substrates that could include AI987662, thereby enhancing its activity if AI987662 is part of a pathway downstream of PKC. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This lipid signaling molecule activates sphingosine-1-phosphate receptors, potentially leading to downstream activation of AI987662 if it is involved in pathways regulated by these receptors. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate is known to inhibit several protein kinases, potentially altering signaling pathways and indirectly enhancing the activity of AI987662 if it is negatively regulated by these kinases. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, which could activate calcium-dependent proteins and pathways that include AI987662, thus enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that could lead to the activation of AI987662 by altering the PI3K/AKT pathway, which has numerous downstream effects, including the modulation of proteins involved in this signaling route. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that may shift the balance of MAPK pathway signaling, which could enhance the activity of AI987662 if it is regulated by MAPK-dependent phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could indirectly activate AI987662 by inhibiting p38 MAPK and shifting signaling toward pathways in which AI987662 is involved. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein acts as a tyrosine kinase inhibitor, and by inhibiting competitive signaling pathways, it may enhance the functional activity of AI987662 if tyrosine kinase signaling negatively regulates AI987662. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), potentially leading to the activation of AI987662 through calcium-dependent signaling pathways. | ||||||